Search Videos and More
News
Dana-Farber Research News 06.15.2025
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from May 16 through May 31.
News
FDA Approves Immune Checkpoint Inhibitor Drug for Patients With Resectable Locally Advanced Head and Neck Cancer
Pembrolizumab, an immune checkpoint inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with resectable locally advanced head and neck squamous cell carcinoma whose tumors express PD-L1 [Combined Positive Score (CPS) ?1] as determined by an FDA-approved test.
News
Double Negative in Cells Could Undermine PARP Inhibitors
There are two ways to fix things: the quick way and the careful one. In cancer, cells with BRCA1 mutations tend to choose the quick fix, leaving them vulnerable to medicines like PARP inhibitors.
Video
Letrozole + Abemaciclib + Metformin Study Presented by Panos Konstantinopoulos, MD, PhD.
Dr. Panos Konstantinopoulos presented the first study of a triplet therapy combining letrozole, abemaciclib, and metformin in any cancer type.
Video
PRISM-AC Study Presented by Abby Rosenberg, MD, MS.
A new psychosocial intervention is showing promising results for adolescents and young adults (AYA) facing advanced cancer.
Video
Colon Cancer Study Presented by Sara Char, MD.
A new study shows that consuming an anti-inflammatory diet could extend overall survival after treatment for stage 3 colon cancer.
Video
NSCLC Study Presented by Julia Rotow, MD.
Dr. Julia Rotow presented results from a study using a cell-free DNA (cfDNA)-guided strategy to personalize first-line treatment for advanced non-small cell lung cancer.
Video
ARC-20 Study Presented by Toni Choueiri, MD.
Toni Choueiri, MD, of Dana-Farber Cancer Institute presents first results from the ARC-20 trial evaluating casdatifan (HIF-2 inhibitor) + cabozantinib (VEGF TKI) in metastatic clear cell kidney cancer.
Video
TRADE Study Presented by Erica Mayer, MD.
Dr. Erica Mayer shares results from the TRADE study showing a successful abemaciclib dose escalation strategy in patients with HR+ breast cancer.
Video
Phase 2 PROSPECT Study Presented by Lakshmi Nayak, MD.
Lakshmi Nayak, MD presented results from a phase 2 PROSPECT study focused on tirabrutinib and it's effect on patients with relapsed or refractory primary central nervous system lymphoma.
Video
Talazoparib + Tazemetostat Presented by Atish Choudhury, MD, PhD.
Dr. Atish Choudhury presented clinical trial results evaluating the combination of talazoparib and tazemetostat in advanced prostate cancer.
Video
DESTINY-Breast09 Presented by Sara Tolaney, MD, MPH.
Dr. Sara Tolaney of Dana-Farber shares pivotal results from the DESTINY-Breast09 phase 3 trial.